IQVIA report outlines key 2018 approvals and more
See summary below and click on image to see full IQVIA 2019 report. "There were 15 therapeutic oncology new active substances (NASs) and one supportive care NAS launched in the United States in 2018. Predictive biomarkers were associated with60% of therapeutic oncology NASs, and three were approved with a companion diagnostic. Precision medicines are having a signi cant impact on the treatment of cancer by stratifying patients into specific groups of patients likely to respon
IQVIA publishes Global Oncology Trends 2019 just in time for ASCO 2019
"A record number of new oncology drugs has been approved in recent years, bringing new treatment options to patients. However, despite robust levels of pipeline activity, oncology remains a challenging area for research and development. This report examines the productivity and output of the oncology pipeline, new treatment mechanisms, and which patients will likely benefit from new therapies." Click on image to see full report at IQVIA
